Navigation Links
Scientists win $2 million to study new pathway in development and maintenance of lymphoma
Date:3/30/2012

JUPITER, FL, March 30, 2012 The National Institutes of Health has awarded The Scripps Research Institute $2 million to study the role of a pathway in the development and maintenance of B-cell lymphoma, a type of cancer that begins in immune system and turns normal disease fighting cells into cancers. The disease affects immune cells known as lymphocytes, which are part of our white blood cells.

John Cleveland, PhD, chair of the Department of Cancer Biology on the Scripps Florida campus, will be the principal investigator for the new five-year study.

B-cell lymphomas tend to occur in older patients and in those people whose immune system has been compromised. It is one of the most common blood cancers in the United States and kills about 20,000 Americans each year.

The new project will focus on the role of Myc oncoproteinsthe products of Myc oncogeneswhich are activated in over half of all human tumor types. Myc oncoproteins accelerate the rate of cell growth, which increases the risk of acquiring additional mutations that allow a premalignant cell to develop into a full-blown tumor. In this project, the Cleveland lab will investigate the role of a pathway that controls the destruction of a class of messenger RNAs (mRNAs) that encode proteins that regulate the development and maintenance of tumors.

"This grant allows us to focus on a new pathway that is controlled by Myc that we think is suitable to target for the development of new anti-cancer drugs," said Cleveland, who has led numerous studies shedding light on this oncogene. "We are very hopeful that learning more about this process will open the door for the development of new treatments."

Specifically, the new project aims to define the mechanisms by which Myc controls the expression and function of Tristetraprolin or TTP, a mRNA-binding protein that normally controls the destruction of a subset of important mRNAs. Importantly, Research Associate Robert Rounbehler, PhD, and other colleagues in the Cleveland lab have shown that TTP functions as a tumor suppressor that impairs the development and maintenance of B lymphoma. Their findings indicating that agents that regulate TTP or affect its key mRNA targets hold great promise as anti-cancer agents.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert  

Related biology news :

1. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
2. Scientists identify novel inhibitor of human microRNA
3. Argonne scientists peer into heart of compound that may detect chemical, biological weapons
4. MU scientists go green with gold, distribute environmentally friendly nanoparticles
5. Scientists identify gene that may contribute to improved rice yield
6. Scientists discover why a mothers high-fat diet contributes to obesity in her children
7. MU scientists see how HIV matures into an infection
8. Earth scientists keep an eye on Texas
9. Thinking it through: Scientists call for policy to guide biofuels industry toward sustainability
10. Scientists identify a molecule that coordinates the movement of cells
11. Scientists Find new migratory patterns for Mediterranean and Western Atlantic bluefin tuna
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists win $2 million to study new pathway in development and maintenance of lymphoma
(Date:11/9/2019)... (PRWEB) , ... November 08, 2019 , ... SiteSeer Technologies, ... Acquisitions as a new client and user of SiteSeer. The boutique real estate ... across the U.S. will use SiteSeer to supplement its own analysis of markets. ...
(Date:11/6/2019)... ... November 06, 2019 , ... ... MD, a senior pharmaceutical industry executive with expertise in clinical pharmacology and pharmacometrics ... and disease strategic data analytics, has joined the firm as an Expert Consultant. ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... for drugs, biologics, gene therapies, and consumer health products, today announced it will ... Sofia, Barcelona, Spain on Nov. 12 – 14, 2019. , On Wednesday, Nov. ...
Breaking Biology News(10 mins):
(Date:11/6/2019)... ... November 06, 2019 , ... LeadingBiotech ... dialogue, today announces its East/West CEO conference to be held January ... , Kicking off the week of the J.P. Morgan Healthcare Conference and ...
(Date:11/5/2019)... TORONTO (PRWEB) , ... November 05, 2019 , ... ... cancer technology, announced it has received CE Mark for its Fusion Bx 2.0 ... semi-robotic arm and user-friendly interface, the Fusion Bx 2.0 will give urologists across ...
(Date:11/2/2019)... ... October 31, 2019 , ... A clinical trial ... each other: study managers, principal investigators, supply chain managers, manufacturers, IRT, CRAs and ... informed of the latest data, potentially leading to patient risk. , By having ...
(Date:11/2/2019)... ... 2019 , ... drug360 graph, a breakthrough knowledge graph product, ... tellic’s expertise in biomedical language processing and machine learning to bear on biomedical ... diseases, variants, phenotypes, and other biomedical entities. Researchers and analysts can use ...
Breaking Biology Technology: